The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and immune modulation of the tumor microenvironment with the combination of the PARP inhibitor rucaparib and CD122-biased agonist NKTR-214.
 
Andrew Simmons
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
Consulting or Advisory Role - Redwood Bioscience
 
Liliane Robillard
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
Research Funding - Clovis Oncology
Travel, Accommodations, Expenses - Clovis Oncology
 
Minh Nguyen
Employment - Clovis Oncology (I)
Stock and Other Ownership Interests - Clovis Oncology
Research Funding - Clovis Oncology
Travel, Accommodations, Expenses - Clovis Oncology (I)
 
Thomas C. Harding
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
Research Funding - Clovis Oncology
Travel, Accommodations, Expenses - Clovis Oncology
 
Deborah H. Charych
Employment - Nektar
Stock and Other Ownership Interests - Nektar
Consulting or Advisory Role - Third Rock Ventures
Research Funding - Nektar
Patents, Royalties, Other Intellectual Property - Nektar
Travel, Accommodations, Expenses - Nektar